Funding granted to researchers by the National Institutes of Health (NIH) powered $94.58 billion in economic activity across ...

The drug in question, called vepdegestrant, is an oral PROteolysis TArgeting Chimera (PROTAC) ER degrader. The phase 3 study ...

Illumina will seek to cut $100 million in expenses by the end of this fiscal year as it plans to deal with a loss of revenue ...

Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...

Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta ...

Siemens Healthineers has obtained new clearances from the FDA for its photon-counting CT scanners, expanding its lineup with two machines aimed at bringing the imaging technology to a wid | Siemens ...

Montreal-based CRO Innovaderm Research has rebranded immediately to Indero, the latest change in an effort to become dually ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...

Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

Lila Sciences is looking to use $200 million in seed funding to develop advanced AI that can power fully autonomous research ...

The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...